Roche sees off patent cliff
The Roche Group continued to face generic competition for its legacy cancer medicines in the first half of 2025, but this was overtaken by double-digit sales increases for some of its newest products and regulatory approvals for several others. At the same time, the disease coverage of the company’s portfolio broadened. Group sales in the first half were CHF 30.9 billion ($33.11 billion), up by 4% in Swiss francs and by 7% in constant exchange rates. The pharmaceuticals division, which accounts for 78% of group sales, generated CHF 24 billion while diagnostics produced CHF 7 billion.
